Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Aleniglipron

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Structure Therapeutics to Present Diabetes Data at ADA 2026
    Structure Therapeutics to Present Diabetes Data at ADA 2026

    27 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/27/3282005/0/en/structure-therapeutics-to-present-aleniglipron-amylin-and-combination-data-at-the-american-diabetes-association-86th-scientific-sessions.html

    GLOBENEWSWIRE
    27 Apr 2026
    Share Share
    Structure Climbs on ‘Competitive’ Profile for Weight Loss Pill
    Structure Climbs on ‘Competitive’ Profile for Weight Loss Pill

    16 Mar 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/structure-climbs-on-highly-competitive-profile-for-weight-loss-pill

    BIOSPACE
    16 Mar 2026
    Share Share
    Structure Therapeutic to Report Data from ACCESS Clinical Program
    Structure Therapeutic to Report Data from ACCESS Clinical Program

    07 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/07/3201156/0/en/Structure-Therapeutics-to-Report-Data-from-ACCESS-Clinical-Program-of-Oral-Small-Molecule-GLP-1-Receptor-Agonist-Aleniglipron-on-December-8-2025.html

    GLOBENEWSWIRE
    07 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.